Regeneron Pharmaceuticals, Inc.
REGN
$828.50
-$5.54-0.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.90% | 3.84% | -0.34% | 2.30% | 5.71% |
| Total Other Revenue | 43.24% | 64.98% | 36.43% | 17.39% | -2.24% |
| Total Revenue | 9.29% | 5.92% | 0.99% | 2.89% | 5.38% |
| Cost of Revenue | 15.29% | 16.09% | 11.95% | 13.18% | 13.94% |
| Gross Profit | 2.61% | -4.75% | -9.97% | -7.08% | -2.75% |
| SG&A Expenses | -1.12% | -6.34% | -8.61% | -6.30% | -1.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -1,900.00% | -- |
| Total Operating Expenses | 10.76% | 9.56% | 5.81% | 7.27% | 9.20% |
| Operating Income | 5.49% | -3.33% | -10.69% | -7.40% | -3.40% |
| Income Before Tax | 5.97% | 3.46% | 9.43% | 3.54% | 6.27% |
| Income Tax Expenses | 101.18% | 51.27% | 97.60% | 80.09% | 56.76% |
| Earnings from Continuing Operations | -2.91% | -1.69% | 2.09% | -1.64% | 3.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.91% | -1.69% | 2.09% | -1.64% | 3.17% |
| EBIT | 5.49% | -3.33% | -10.69% | -7.40% | -3.40% |
| EBITDA | 5.27% | -1.97% | -8.26% | -5.44% | -1.81% |
| EPS Basic | 0.38% | 1.85% | 5.49% | 0.50% | 3.58% |
| Normalized Basic EPS | 28.63% | 22.09% | 15.45% | -2.54% | 0.81% |
| EPS Diluted | 1.93% | 4.45% | 8.53% | 3.36% | 5.11% |
| Normalized Diluted EPS | 30.60% | 24.98% | 18.56% | 0.11% | 2.16% |
| Average Basic Shares Outstanding | -3.32% | -3.46% | -3.08% | -1.76% | -0.30% |
| Average Diluted Shares Outstanding | -4.76% | -5.61% | -5.65% | -4.28% | -1.73% |
| Dividend Per Share | 106.82% | 306.82% | -- | -- | -- |
| Payout Ratio | 1.09% | 3.06% | -- | -- | -- |